Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2637MR)

This product GTTS-WQ2637MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001290023.2; NM_001258214.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3594; 3595
UniProt ID P42701; Q99665
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2637MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ743MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ15937MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ10307MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ9105MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ6807MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ8085MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ10862MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ13367MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1498487
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW